Ling Shi Tan
Vorstandsvorsitzender bei dMed Biopharmaceutical Technology (Shanghai) Co., Ltd.
Aktive Beziehungen
Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
---|---|---|---|---|
Wing Yu Leung | F | 53 |
dMed Biopharmaceutical Technology (Shanghai) Co., Ltd.
dMed Biopharmaceutical Technology (Shanghai) Co., Ltd. Pharmaceuticals: MajorHealth Technology DMed Biopharmaceutical Technology Shanghai Co., Ltd. engages in the development of medicines and medical devices. The company was founded by Ling Shi Tan on August 3, 2016 and is headquartered in Shanghai, China. | - |
Shan Fu | M | 56 |
dMed Biopharmaceutical Technology (Shanghai) Co., Ltd.
dMed Biopharmaceutical Technology (Shanghai) Co., Ltd. Pharmaceuticals: MajorHealth Technology DMed Biopharmaceutical Technology Shanghai Co., Ltd. engages in the development of medicines and medical devices. The company was founded by Ling Shi Tan on August 3, 2016 and is headquartered in Shanghai, China. | - |
Barbara Lopez-Kunz | F | 66 |
dMedClinical Co., Ltd.
dMedClinical Co., Ltd. Miscellaneous Commercial ServicesCommercial Services dMedClinical Co. Ltd., formerly known as Caidya, is a leading clinical research organization that offers medical writing services for clinical trials. The company is based in Shanghai, CN, and has subsidiaries in Germany, Switzerland, United States, United Kingdom, and China. The Chinese company uses a combination of industry-recognized, proprietary, and third-party technologies to ensure transparency and cost efficiency in clinical trials. The company specializes in infectious disease clinical trial services and provide expertise for therapeutic developments. dMedClinical Co. was founded in 2021 by Ling Shi Tan, who has been the CEO since then. | 2 Jahre |
Simon Britton | M | - |
dMedClinical Co., Ltd.
dMedClinical Co., Ltd. Miscellaneous Commercial ServicesCommercial Services dMedClinical Co. Ltd., formerly known as Caidya, is a leading clinical research organization that offers medical writing services for clinical trials. The company is based in Shanghai, CN, and has subsidiaries in Germany, Switzerland, United States, United Kingdom, and China. The Chinese company uses a combination of industry-recognized, proprietary, and third-party technologies to ensure transparency and cost efficiency in clinical trials. The company specializes in infectious disease clinical trial services and provide expertise for therapeutic developments. dMedClinical Co. was founded in 2021 by Ling Shi Tan, who has been the CEO since then. | - |
Rui Zhe Zhao | M | - |
dMed Biopharmaceutical Technology (Shanghai) Co., Ltd.
dMed Biopharmaceutical Technology (Shanghai) Co., Ltd. Pharmaceuticals: MajorHealth Technology DMed Biopharmaceutical Technology Shanghai Co., Ltd. engages in the development of medicines and medical devices. The company was founded by Ling Shi Tan on August 3, 2016 and is headquartered in Shanghai, China. | - |
Ying Shi Qian | M | - |
dMed Biopharmaceutical Technology (Shanghai) Co., Ltd.
dMed Biopharmaceutical Technology (Shanghai) Co., Ltd. Pharmaceuticals: MajorHealth Technology DMed Biopharmaceutical Technology Shanghai Co., Ltd. engages in the development of medicines and medical devices. The company was founded by Ling Shi Tan on August 3, 2016 and is headquartered in Shanghai, China. | - |
John Roberts | M | 65 |
dMedClinical Co., Ltd.
dMedClinical Co., Ltd. Miscellaneous Commercial ServicesCommercial Services dMedClinical Co. Ltd., formerly known as Caidya, is a leading clinical research organization that offers medical writing services for clinical trials. The company is based in Shanghai, CN, and has subsidiaries in Germany, Switzerland, United States, United Kingdom, and China. The Chinese company uses a combination of industry-recognized, proprietary, and third-party technologies to ensure transparency and cost efficiency in clinical trials. The company specializes in infectious disease clinical trial services and provide expertise for therapeutic developments. dMedClinical Co. was founded in 2021 by Ling Shi Tan, who has been the CEO since then. | - |
Beziehungs-Chart
Beziehungen zu mehreren Unternehmen
Statistik
Land | Beziehungen | % des Gesamten |
---|---|---|
China | 4 | 57,14% |
Vereinigte Staaten | 3 | 42,86% |
Alter der Beziehungen
Aktive
Vergangene
Herr
Frau
Aufsichtsräte
Führungskräfte
Ursprung der Beziehungen
- Börse
- Insiders
- Ling Shi Tan
- Persönliches Netzwerk